Can WuXi PharmaTech Meet These Numbers?
WuXi PharmaTech (NYS: WX) is expected to report Q2 earnings on Aug. 13. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict WuXi PharmaTech (Cayman)'s revenues will expand 24.6% and EPS will improve 24.0%.
The average estimate for revenue is $125.9 million. On the bottom line, the average EPS estimate is $0.31.
Last quarter, WuXi PharmaTech booked revenue of $118.0 million. GAAP reported sales were 26% higher than the prior-year quarter's $93.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, non-GAAP EPS came in at $0.33. GAAP EPS of $0.29 for Q1 were 21% higher than the prior-year quarter's $0.24 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 35.5%, 160 basis points worse than the prior-year quarter. Operating margin was 17.5%, 370 basis points worse than the prior-year quarter. Net margin was 17.8%, 170 basis points worse than the prior-year quarter.
The full year's average estimate for revenue is $486.4 million. The average EPS estimate is $1.26.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 330 members out of 350 rating the stock outperform, and 20 members rating it underperform. Among 73 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 68 give WuXi PharmaTech a green thumbs-up, and five give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on WuXi PharmaTech is outperform, with an average price target of $17.68.
- Add WuXi PharmaTech (Cayman) to My Watchlist.
The article Can WuXi PharmaTech Meet These Numbers? originally appeared on Fool.com.Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.